2022
Modeling the cost‐effectiveness and impact on fatal overdose and initiation of buprenorphine–naloxone treatment at syringe service programs
Adams JW, Savinkina A, Fox A, Behrends CN, Madushani RWMA, Wang J, Chatterjee A, Walley AY, Barocas JA, Linas BP. Modeling the cost‐effectiveness and impact on fatal overdose and initiation of buprenorphine–naloxone treatment at syringe service programs. Addiction 2022, 117: 2635-2648. PMID: 35315148, PMCID: PMC9951221, DOI: 10.1111/add.15883.Peer-Reviewed Original ResearchConceptsSyringe services programFatal opioid overdosesBuprenorphine-naloxone treatmentOpioid use disorderTreatment initiationBuprenorphine treatmentOpioid overdosesFatal overdosesSSP clientsActive opioid useCommunity treatment providersObservational cohort studyNational surveillance dataCost-effectiveness analysisCohort studyIntervention scenariosOpioid useBuprenorphine programOUD treatmentStatus quo scenarioClinical trialsFatal overdoseMore QALYsUse disordersTreatment engagement
2021
Projected Estimates of Opioid Mortality After Community-Level Interventions
Linas BP, Savinkina A, Madushani RWMA, Wang J, Yazdi G, Chatterjee A, Walley AY, Morgan JR, Epstein RL, Assoumou SA, Murphy SM, Schackman BR, Chrysanthopoulou SA, White LF, Barocas JA. Projected Estimates of Opioid Mortality After Community-Level Interventions. JAMA Network Open 2021, 4: e2037259. PMID: 33587136, PMCID: PMC7885041, DOI: 10.1001/jamanetworkopen.2020.37259.Peer-Reviewed Original ResearchConceptsCommunity-level interventionsOverdose mortalityOpioid overdoseUse of MOUDDistribution of naloxoneOpioid overdose deathsDecision analytical modelOpioid overdose ratesMOUD retentionOUD populationOpioid mortalityMAIN OUTCOMEMOUDNaloxone distributionOverdose deathsOverdose ratesSingle interventionMortalityNaloxoneInterventionMonthsOverdoseProjected estimatesHuman ServicesOutcomes